Human — controlled trial

Zinc promotes microbial p-coumaric acid production that protects against cholestatic liver injury

Cholestatic liver disease (CLD) is a common liver disorder with limited treatment options. Here, we demonstrate that zinc (Zn) supplementation can alter the gut microbiome to mitigate cholestatic liver injury. Oral Zn altered the microbiota of mice and humans (this study was registered at clinicaltrials.gov [NCT05597137]), increasing the abundance of Blautia producta (B. producta) and promoting the generation of p-coumaric acid. Additionally, p-coumaric acid concentratio…

Cited by

NAD+
What the research on NAD+ actually shows
The indexed literature on NAD+ includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether NAD+ is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.

Compounds examined

NAD+

Study records state what a paper reported. PepIndex does not interpret findings, assess clinical significance, or restate results in language implying an application not present in the source. Last reviewed 23 Jul 2026.